博文
全国首个基因与细胞治疗“风险分级、准入分类”管理制度
||
全国首个基因与细胞治疗“风险分级、准入分类”管理制度
https://mp.weixin.qq.com/s/rg7YIcXdPFksnrpFtgq9ng
http://www.pubmedplus.cn/P/SearchQuickResult?wd=bdd4d641-a50b-4a46-8e43-4236b647976a
| 01. | 2021 | 3 篇 | 6.522% |
| 02. | 2020 | 1 篇 | 2.174% |
| 03. | 2019 | 1 篇 | 2.174% |
| 04. | 2018 | 1 篇 | 2.174% |
| 05. | 2017 | 4 篇 | 8.696% |
| 06. | 2015 | 2 篇 | 4.348% |
| 07. | 2012 | 3 篇 | 6.522% |
| 08. | 2011 | 4 篇 | 8.696% |
| 09. | 2010 | 3 篇 | 6.522% |
| 10. | 2009 | 4 篇 | 8.696% |
| 01. | blood | 6 篇 | 13.043% |
| 02. | hum gene ther | 3 篇 | 6.522% |
| 03. | j clin invest | 3 篇 | 6.522% |
| 04. | hematol oncol clin north am | 2 篇 | 4.348% |
| 05. | hematology am soc hematol educ program | 2 篇 | 4.348% |
| 06. | j allergy clin immunol | 2 篇 | 4.348% |
| 07. | j clin immunol | 2 篇 | 4.348% |
| 08. | mol ther | 2 篇 | 4.348% |
| 09. | n engl j med | 2 篇 | 4.348% |
| 10. | science | 2 篇 | 4.348% |
| 01. | 美国 | 21 篇 | 45.652% |
| 02. | 意大利 | 12 篇 | 26.087% |
| 03. | 英国 | 7 篇 | 15.217% |
| 04. | 法国 | 4 篇 | 8.696% |
| 05. | 德国 | 3 篇 | 6.522% |
| 06. | 瑞士 | 2 篇 | 4.348% |
| 07. | 丹麦 | 1 篇 | 2.174% |
| 08. | 日本 | 1 篇 | 2.174% |
| 没有聚类出数据 |
| 01. | Genetic Therapy | 46 篇 | 100.000% |
| 02. | Hematopoietic Stem Cell Transplantation | 46 篇 | 100.000% |
| 03. | Severe Combined Immunodeficiency | 46 篇 | 100.000% |
| 04. | Humans | 42 篇 | 91.304% |
| 05. | Adenosine Deaminase | 27 篇 | 58.696% |
| 06. | Genetic Vectors | 23 篇 | 50.000% |
| 07. | Animals | 21 篇 | 45.652% |
| 08. | Hematopoietic Stem Cells | 17 篇 | 36.957% |
| 09. | Transduction, Genetic | 16 篇 | 34.783% |
| 10. | Retroviridae | 15 篇 | 32.609% |
https://wap.sciencenet.cn/blog-280034-1368334.html
上一篇：国际病原基因诊断能力
下一篇：为什么致命卵巢癌对免疫治疗有耐药性
